Division of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-Cho, Chuo-Ku, Kobe, Hyogo, 650-0017, Japan.
Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, 7-5-1 Kusunoki-Cho, Chuo-Ku, Tokyo, 113-8655, Japan.
J Gastroenterol. 2023 Mar;58(3):277-291. doi: 10.1007/s00535-022-01939-8. Epub 2023 Jan 27.
Tertiary lymphoid structure (TLS) reflects an intense immune response against cancer, which correlates with favorable patient survival. However, the association of TLS with tumor-infiltrating lymphocytes (TILs) and clinical outcomes has not been investigated comprehensively in pancreatic ductal adenocarcinoma (PDAC).
We utilized an integrative molecular pathological epidemiology database on 162 cases with resected PDAC, and examined TLS in relation to levels of TILs, patient survival, and treatment response. In whole-section slides, we assessed the formation of TLS and conducted immunohistochemistry for tumor-infiltrating T cells (CD4, CD8, CD45RO, and FOXP3). As confounding factors, we assessed alterations of four main driver genes (KRAS, TP53, CDKN2A [p16], and SMAD4) using next-generation sequencing and immunohistochemistry, and tumor CD274 (PD-L1) expression assessed by immunohistochemistry.
TLSs were found in 112 patients with PDAC (69.1%). TLS was associated with high levels of CD4 TILs (multivariable odds ratio [OR], 3.50; 95% confidence interval [CI] 1.65-7.80; P = 0.0002), CD8 TILs (multivariable OR, 11.0; 95% CI 4.57-29.7, P < 0.0001) and CD45RO TILs (multivariable OR, 2.65; 95% CI 1.25-5.80, P = 0.01), but not with levels of FOXP3 TILs. TLS was associated with longer pancreatic cancer-specific survival (multivariable hazard ratio, 0.37; 95% CI 0.25-0.56, P < 0.0001) and favorable outcomes of adjuvant S-1-treatment. TLS was not associated with driver gene alterations but tumor CD274 negative expression.
Our comprehensive data supports the surrogacy of TLS for vigorous anti-tumor immune response characterized by high levels of helper and cytotoxic T cells and their prognostic role.
三级淋巴结构(TLS)反映了针对癌症的强烈免疫反应,与患者的生存预后相关。然而,在胰腺导管腺癌(PDAC)中,TLS 与肿瘤浸润淋巴细胞(TILs)和临床结局的关联尚未得到全面研究。
我们利用了一个包含 162 例接受手术治疗的 PDAC 患者的整合分子病理流行病学数据库,并研究了 TLS 与 TILs 水平、患者生存和治疗反应的关系。在全切片上,我们评估了 TLS 的形成,并进行了肿瘤浸润 T 细胞(CD4、CD8、CD45RO 和 FOXP3)的免疫组织化学检测。作为混杂因素,我们使用下一代测序和免疫组织化学评估了四个主要驱动基因(KRAS、TP53、CDKN2A[p16]和 SMAD4)的改变,并用免疫组织化学评估了肿瘤 CD274(PD-L1)的表达。
在 112 例 PDAC 患者中发现了 TLS(69.1%)。TLS 与高水平的 CD4 TILs(多变量优势比 [OR],3.50;95%置信区间 [CI],1.65-7.80;P=0.0002)、CD8 TILs(多变量 OR,11.0;95% CI,4.57-29.7,P<0.0001)和 CD45RO TILs(多变量 OR,2.65;95% CI,1.25-5.80,P=0.01)相关,但与 FOXP3 TILs 水平无关。TLS 与胰腺癌特异性生存时间延长相关(多变量风险比,0.37;95% CI,0.25-0.56,P<0.0001),并与辅助 S-1 治疗的良好结局相关。TLS 与驱动基因改变无关,但与肿瘤 CD274 阴性表达相关。
我们的综合数据支持 TLS 作为强有力的抗肿瘤免疫反应的替代标志物,其特征是高水平的辅助和细胞毒性 T 细胞及其预后作用。